Dr. Andrew Loblaw, MD
Claim this profileSunnybrook Health Sciences Centre
Studies Prostate Cancer
Studies Recurrence
7 reported clinical trials
9 drugs studied
Area of expertise
1Prostate Cancer
Stage III
Stage I
Stage II
2Recurrence
Affiliated Hospitals
Clinical Trials Andrew Loblaw, MD is currently running
Rectal Hydrogel Spacer
for Prostate Cancer
There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy. Gastrointestinal (GI) toxicity with salvage radiotherapy range between14-58%, respectively for patients undergoing re-irradiation. There is a concern for an increased risk of fistula development in these patients who receive second course of radiation. Hypofractionation using SABR has been utilized in the re-irradiation setting for prostate cancer with good tumor control and toxicity outcomes. In order to decrease the rectal toxicity, dose to the rectum should be kept as low as possible. Several techniques can be used to achieve this: tighter dosimetric dose painting, better patient or organ immobilization or use of a biodegradable gel. The Investigators ropose a phase I study to assess placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
Recruiting1 award N/A
Ablative Radiotherapy
for Prostate Cancer
Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.
Recruiting1 award Phase 2 & 35 criteria
More about Andrew Loblaw, MD
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Andrew Loblaw, MD has experience with
- HDR
- Stereotactic Ablative Body Radiotherapy
- Focal Salvage HDR Brachytherapy
- HDR Brachytherapy
- Hypofractionation
- Conventional Fractionation
Breakdown of trials Andrew Loblaw, MD has run
Prostate Cancer
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew Loblaw, MD specialize in?
Andrew Loblaw, MD focuses on Prostate Cancer and Recurrence. In particular, much of their work with Prostate Cancer has involved Stage III patients, or patients who are Stage I.
Is Andrew Loblaw, MD currently recruiting for clinical trials?
Yes, Andrew Loblaw, MD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Andrew Loblaw, MD has studied deeply?
Yes, Andrew Loblaw, MD has studied treatments such as HDR, Stereotactic Ablative Body Radiotherapy, Focal Salvage HDR Brachytherapy.
What is the best way to schedule an appointment with Andrew Loblaw, MD?
Apply for one of the trials that Andrew Loblaw, MD is conducting.
What is the office address of Andrew Loblaw, MD?
The office of Andrew Loblaw, MD is located at: Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada. This is the address for their practice at the Sunnybrook Health Sciences Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.